Member Info for VikR

Somebody had alluded to on X the results being stellar, but it was since conveniently deleted. Based on what we know thus far though expect and hope they are exceptional.

What is happening here minus 25k in the red now

Did not expect to see this

SG needs to get some positive news out

Between this and JAN my largest holdings in gold exploration with huge untapped potential

Can now sell £40k at a time for 2.01 p

Bodes well as we get more interest and new shareholders on the radar

JAN on the move this morning

Probably the most underrated gold explorer of 2026, if I wasn’t so much in the red here wood probably sell out of here to buy in there. Expecting a miracle here now with this protracted quiet period

There are big gaps on the chart up to double figures, expect an OMI style re rate when you least expect it. Having indigenous Brazilian nationals leading this project is the biggest blessing JAN can ever have. Most geologists have to fly to site and work remotely to manage operations. These guys have got Luis the solicitor managing the regulatory hurdles and Paulo managing contractors and getting them on ground. Who gets access to 3 drills in one week, only contacts can do that for you. Hugo working in the UK to drive up institutional interest makes this for an unstoppable A team.

New investors do your due diligence, this is not just ramping anymore but substantiated factual claims.

Expect life changing returns

For the skeptics who are still debating on the email, the chap has just given a generic response and gone to the effort to respond. Not sure why everyone is making a mountain out of a molehill, read below for absolute proof copy and paste, the level of trust here is abysmal.

Good morning,

OOPD cannot provide status updates on submissions under review by the Agency. Please note that staffing changes at the beginning of 2025 have impacted our ability to maintain our internal policy for 90-day reviews. We ask for your patience as our office continues to review applications as fast as is accurately possible.

Kind regards,

Corey

Corey Burns, MPH

Project Management Officer

Office of Orphan Products Development

U.S. Food and Drug Administration

(240) 402-4036

orphan@fda.hhs.gov

-----Original

Sent: Thursday, February 19, 2026 4:09 AM

To: OPDAR <OPDAR@fda.hhs.gov>

Subject: [EXTERNAL] Fwd: NXP002 (inhaled tranilast) for IPF URGENT

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi

I agree the excuse regarding the 2025 staffing changes should not really be relevant to a delay in 2026, who knows we certainly don’t

For any of the skeptics regarding the email won’t do you send an email yourself and see what response you get. It did not take me long to track the email address down:

orphan@fda.hhs.gov

Not sure what anyone thinks one has to gain by making fictitious claims. Since joining and buying big here recently I have done a lot of due diligence and being proactive by tracking the email and sending and then sharing the response I have been proactive then most. I still maintain confidence of a successful outcome here sooner rather then later

I don’t think it’s AI generated as it had the officers credentials/name and phone number on the bottom. When I googled the name the aforementioned person does work there. I know it doesn’t tell us what we already know however at least it explains the delay in part and also they are working as quickly as possible.

Reply from FDA

OOPD cannot provide status updates on submissions under review by the Agency. Please note that staffing changes at the beginning of 2025 have impacted our ability to maintain our internal policy for 90-day reviews. We ask for your patience as our office continues to review applications as fast as is accurately possible.

Daily progress in increments is good

Today I can get an offer of 1.80p to sell £35k worth, demand is there but hope these new round of investors can hold more then 5 minutes for the true substantive re rate which has now been emphasised on all fronts and even by comparators of similar outfits is significantly undervalued.

Looking forward to a market cap of £50 million plus and watch the SP follow in tandem

US investors are heavily vested in making the Jameson drill a success, interest travels all the way to the top government level, Trump knows the stakes here and just imagine a tweet from him on the subject matter. NasDAQ listing will set this alight, anyone who thinks otherwise sell now or hold for the real re rate

If investors have waited this far it makes no sense to sell out at such a pivotal inflection point moment. Risk to reward at this stage for me favours the latter considerably at present.

Confident of news soon

I’m running out of funds to keep on topping up below 2p. I own more then Hugo unless he has bought more on the open market and I know of at least 2 colleagues who also hold 10 million between them. These shares are all locked away and not traded reducing the free float even further from the MMs. I don’t have any plans to trim until this reaches double figures for me.

I have also emailed: orphan@fda.hhs.gov to ascertain current state of play and ask them to expedite there decision making process. Put all the commercial aspects to one side we need new treatments to really help the patients suffering worldwide and give them some improvement in their symptoms and lead a better quality of life.

Activities need to be ramped up now and get tranilast into clinical trials

That’s good news from the FDA that they have approved Deupirfenidone (LYT-100) ODD. That drug is more advanced in clinical trials however the area is so underserved there is room for both. Additionally inhaled will always be safer and better tolerated with less side effects and cheaper to run the clinical trials and manufacture.

‘There are over 232,000 people in the US and the EU5 countries (Italy, Spain, France, Germany and the United Kingdom) living with IPF. Of the 3 approved FDA treatments only about 25% of IPF patients have ever been treated with either FDA-approved therapeutic (pirfenidone and nintedanib). yet combined sales of these medications in 2022 were more than $4 billion representing a significant market opportunity in IPF and other fibrotic lung diseases’

Pure tech is the company developing it, check out the page below for the wealth of research on IPF and stats etc

https://www.puretechhealth.com/programs/details/lyt-100

This is really reassuring news and we remain on the right track,

Pulmonary fibrosis is a definite money maker clinical area and I’m convinced pharma will not this opportunity pass by post ODD approval

The demand is certainly there, I am able to sell £25k chunks for 1.72p, fortunately I did not press the sell button by accident that would have been catastrophic.

Yes my research has alluded to the same.

Having studied A-level chemistry some 20 years ago brings back some knowledge. It is a very finite resource and will be needed more and more in the future coupled with not enough resource to meet demand. This alone makes rockfire stand out by a country mile based on this one critical metal alone, it seems the cumulative resource has not been grasped by the market or understood in its entirety. I seldom recommend trading against the market as you will most likely always lose but I think they have priced this wrong and it should not be in the lowly 0.2's

That is the case but during that time several key things have happened

- more clinical data to support the mechanism of action and therapeutic effect

- grant of multiple patent protections

- ODD in Europe with USA pending

Each milestone has made it more commercially attractive. Pharma partners want all the steps done for them before committing, we are now the closest we have ever been to deal conclusion. Just a bit more patience for ODD sign off from the FDA and this shall fly